Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Receivables - Other for 9 consecutive years, with $1.0 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Other fell 50.0% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 50.0% decrease, with the full-year FY2025 number at $1.0 million, down 50.0% from a year prior.
- Receivables - Other was $1.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $2.1 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $16.0 million in Q4 2021 to a low of $200000.0 in Q1 2024.
- A 5-year average of $3.7 million and a median of $2.4 million in 2023 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: tumbled 98.43% in 2024, then surged 1100.0% in 2025.
- Ultragenyx Pharmaceutical's Receivables - Other stood at $16.0 million in 2021, then tumbled by 60.0% to $6.4 million in 2022, then plummeted by 82.81% to $1.1 million in 2023, then skyrocketed by 81.82% to $2.0 million in 2024, then plummeted by 50.0% to $1.0 million in 2025.
- Per Business Quant, the three most recent readings for RARE's Receivables - Other are $1.0 million (Q4 2025), $2.1 million (Q3 2025), and $900000.0 (Q2 2025).